Towards Healthcare
Genome Editing Market | Shares | Companies Report by 2033

Genome Editing Market Size (USD 38.43 Billion) Report by 2033

The report covers Genome Editing Market Segments categorized in terms of applications addressing genetic engineering, encompassing cell line engineering, animal genetic engineering, plant genetic engineering and others. Clinical applications explores diagnostics and therapy development. Technologies highlights CRISPR/Cas9, TALENs/MegaTALs, ZFN, Meganuclease and other methods. Delivery methods are ex-vivo and in-vivo approaches. End-users includes biotechnology and pharmaceutical companies, academic and government research institutes, as well as contract research organizations. The report offers the value (in USD Billion) for the above segments.

Genome Editing Market Size, Manufacturers and Future Analysis Report

The genome editing market size reached US$ 8.03 billion in 2023 and is projected to hit around US$ 38.43 billion by 2033, expanding at a CAGR of 16.95% during the forecast period from 2024 to 2033. Applications in various industries promote the growth of the genome editing market.

Genome Editing Market Revenue 2023 - 2033

Unlock Infinite Advantages: Subscribe to Annual Membership

Key Takeaways

  • North America has held a major revenue share of 48% in 2023.
  • Asia Pacific is expected to grow at the fastest CAGR of 18.77% during the forecast period.
  • By application, the genetic engineering segment dominated the market in 2023.
  • By application, the clinical application segment is expected to expand at a solid CAGR of 13.20% during the forecast period.
  • By technology, the CRISPR/Cas9 segment has contributed more than 44% of revenue share in 2023.
  • By technology, the ZFN segment is projected to grow with a significant CAGR of 16.58%during the forecast period.
  • By the delivery method, the ex-vivo segment has generated more than 52% of revenue share in 2023.
  • By the delivery method, the in-vivo segment is estimated to grow at a solid CAGR of 19.95% during the forecast period.
  • By end-use, the biotechnology and pharmaceutical companies segment has recorded more than 52% of revenue share in 2023.
  • By end-use, the academic and research institutions segment is expanding at a notable CAGR of 19.24% during the forecast period.

Industry at a Glance

The genome editing market offers a range of techniques for changing the genetic makeup of living organisms, is booming, and represents the cutting edge of biotechnological innovation. Thanks to a suite of technologies known as genome editing, also sometimes called gene editing.

Scientists may now modify an organism's DNA. With the use of these techniques, genetic material may be added, removed, or modified at certain genomics locations. Many techniques have been developed to alter DNA. Unlike previous genetic engineering techniques that randomly inserted genetic material across the genome, genome editing targets specific locations inside the host genome for genetic material insertions.

The genome editing market is significantly growing due to its application in research, disease diagnosis & treatment, genetically modified organizations, drug discovery, therapeutics development, and so on. Technological advancements and continuous innovation by key organizations and governments will boost the growth of the market in the future.

Top Companies in the Genome Editing Market

  • Thermo Fisher Scientific, Inc
  • Lonza
  • Bluebird Bio, Inc.
  • OriGene Technologies, Inc.
  • New England Biolabs
  • Genscript Biotech Corp
  • Transposagen Biopharmaceuticals, Inc.
  • Danaher Corporation
  • Horizon Discovery Ltd. (Revvity, Inc.)
  • Takara Bio Inc.
  • AstraZeneca
  • Cellectis S.A.
  • Caribou Biosciences, Inc
  • Intellia Therapeutics, Inc.
  • CRISPR Therapeutics
  • Precision BioSciences
  • Editas Medicine
  • Sangamo Therapeutics
  • Recombinetics
  • Cibus Inc.
  • Merck KGaA

CRISPR Therapeutics Pipeline in Genome Editing

Company Name CRISPR Therapeutics
Headquarters Zug, Switzerland

The following list is of the genome editing pipeline:

  • Exagamglogene Autotemcel (exa-cel): β-thalassemia (Approved in some countries)
  • Exagamglogene Autotemcel (exa-cel): Sickle cell disease (Approved in some countries)
  • CTX211: Type 1 diabetes mellitus (Clinical Trial)
  • CTX320: Lp(a) for cardiovascular disease (Clinical Trial)
  • CTX310: ANGPTL3 for cardiovascular disease (Clinical Trial)
  • CTX131: Anti-CD70 allogeneic Car T (Clinical Trial)
  • CTX112: Anti-CD19 allogeneic CAR T (Clinical Trial)

Caribou Biosciences, Inc. Pipeline in Genome Editing

Company Name Caribou Biosciences Inc.
Headquarters California, U.S.
Pipeline In April 2024, Caribou Biosciences, Inc. is a prominent clinical-stage CRISPR genome-editing biopharmaceutical company. The company announced that the FDA had approved its Investigational New Drug (IND) application for CB-010, an allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (KO), to treat extrarenal lupus (ERL) and lupus nephritis (LN). It is anticipated that by the end of 2024, a multicenter, open-label GALLOP clinical study including CB-010 in patients with LN and ERL would begin phase 1.

The Use in the Prevention and Treatment of Diseases is Driving the Market

The Use in the Prevention and Treatment of Diseases is Driving the Market

With further use in the works, genome editing is already or will soon be available in clinics to treat a number of disorders that are driving the growth of the genome editing market. Active measures must be taken to guarantee that this ground-breaking technology is used responsibly to treat, cure, and prevent genetic illnesses, given the field's fast speed.

With the advent of high-throughput genomic screening, comparative analysis of human genome sequences, and lower costs associated with genome sequencing, the field of genetic illness diagnosis has advanced quickly. The possibility of correcting disease-causing germline mutations by genome editing presents a way to induce genetic alterations that would be inherited by subsequent generations.

For instance,

  • In July 2022, the gene editing platform VERVE-101, which employs a precise type of base editing, is being tested for safety and acceptability. Verve Therapeutics has reported that it has dosed the first subject in the experiment. For individuals suffering from heterozygous familial hypercholesterolemia (HeFH), a genetic subtype of cardiovascular disease that is associated with elevated cholesterol, VERVE-101 can inactivate a liver-expressed gene linked to high cholesterol by altering a single DNA nucleotide.

Off-target Effect of CRISPR Restraints the Growth of the Genome Editing Market

Although CRISPR has a great deal of potential as a genome-editing tool, there are still a few issues that need to be resolved before applying. One of the biggest obstacles to CRISPR gene editing is off-target DNA cleavage, which happens when the molecular scissors cut into the wrong part of the host genome, changing the genome in a way that is non-specific, undesirable, unanticipated, or even harmful, rather than correcting these flaws. The mechanism creates genetic mutations. Many techniques, including prime editing, off-target identification, sgRNA optimization, Cas9 nuclease modification, and others, have been developed to lessen the impacts of off-targeting.

Gene Therapy Holds a Great Opportunity for the Genome Editing Market

Millions of people worldwide suffer from rare genetic disorders. The majority of them are brought on by faulty genes that lower life expectancy and increase the risk of dying young. Genetic therapies are seen to be the most promising treatment for uncommon genetic illnesses since they attempt to correct or replace damaged genes. Currently, only around 5 percent of rare genetic illnesses have approved medicines. These diseases have few therapeutic alternatives. However, it is anticipated that genetic medicines will transform the management of uncommon genetic illnesses in the future.

Report Highlights

Application Insights

By application, the genetic engineering segment dominated the genome editing market in 2023. Genome editing is a type of genetic engineering. It is a crucial research tool that makes it possible to examine the role of particular genes. Medications, vaccines, and other goods have been extracted from creatures that were genetically modified to generate them. Crops have been designed to increase production, nutritional value, and resistance to environmental pressures in order to help ensure food security. For natural scientists, genetic engineering is a valuable tool, and the development of transgenic organisms is one of the most significant tools for the study of gene function.

For instance,

  • In April 2024, Italy contemplated conducting the first field test of genetically altered rice to resist illness without agrochemicals. Rice can fend off the Pyricularia oryzae fungus, which produces the illness known as "brusone," without the need for fungicides. Thanks to modern genomic procedures known in Italy as TEA, or assisted evolution techniques, experimental seeding of a variety of rice in an open field was approved with finality by the Ministry of the Environment.

By application, the clinical application segment is expected to grow at the fastest rate during the forecast period. Gene therapy, medication production, and the development of model animals with characteristics similar to human health are just a few of the numerous medical uses of genetic engineering. Human albumin, monoclonal antibodies, antihemophilic factors, follicle-stimulating hormones (used to treat infertility), human growth hormones, and several other medications have all been subject to this use. Genome editing is becoming increasingly necessary because of the increasing number of genetic abnormalities brought on by population growth and changing environmental factors.

For instance,

  • The incidence of down syndrome is thought to be between 1 in 1,000 and 1 in 1,100 live births globally, according to the World Health Organization. This particular chromosomal abnormality affects between 3,000 and 5,000 newborns annually.
  • According to the National Heart, Lung, and Blood Institute, about 100,000 Americans and 20 million people worldwide are affected by sickle cell anemia.

Technology Insights

By technology, the CRISPR/Cas9 segment dominated the genome editing market in 2023 and is expected to grow at the fastest CAGR during the forecast period. Because of its straightforward operation, simple design, low cost, and great efficiency, CRISPR/Cas9 technology has emerged as the most studied gene editing technique in recent years. Studying genes or genomic functions in humans, animals, plants, and microbes has demonstrated significant promise thanks to CRISPR/Cas9. Technology utilizing CRISPR/Cas9 has the ability to not only treat diseases but even modify aging and extend human lifespans. These arguments support the idea that further research on the CRISPR/Cas system's potential applications will be beneficial to humanity in the long run. It is possible to preserve physical health conditions and treat all incurable diseases by using the CRISPR/Cas system.

For instance,

  • In April 2025, in an alliance that will see Regeneron Pharmaceuticals expand its genetic medicine business through the addition of additional gene editing programs, the companies announced that Regeneron will leverage Mammoth Biosciences' ultracompact, CRISPR-based gene editing platform to create in vivo treatments for non-hepatic tissues and cell types.

By technology, the ZFN is expected to grow with significant growth during the forecast period. Targetable DNA cleavage reagents known as zinc-finger nucleases (ZFNs) have been found to be widely used as instruments for targeting certain genes. ZFNs are a revolutionary tool with the potential to change personalized therapy and improve biological research. Numerous plants and animals can have their genomes altered with the use of zinc finger nucleases. ZFNs are also employed in the development of isogenic human illness models, a new class of genetic disease models. All of the issues related to the viral delivery of therapeutic genes may be avoided with the plasmid-based strategy that encodes ZFN.

Delivery Method Insights

By the delivery method, the ex-vivo segment dominated the genome editing market in 2023. In this delivery method, cells are removed from the body, genetic material is altered, and then the modified cells are delivered back into the body. One benefit of the ex vivo delivery method is that the entire process of generating new genetic material may be managed. It is possible to confirm the new genetic material's health using ex vivo techniques prior to a person receiving it. Blood-related illnesses are the most common uses of ex vivo gene therapy. This covers various malignancies, including certain forms of lymphoma, leukemia, and hereditary illnesses. Future uses for ex vivo gene therapy could include treating diseases other than blood and neurological conditions brought on by a genetic flaw. Researchers are trying to find treatments for autoimmune illnesses like lupus, neurological disorders like leukodystrophies, and other hereditary abnormalities. They are also trying to cure a compromised, malfunctioning, or aberrant immune system, boosting this segment's growth in the genome editing market.

By the delivery method, the in-vivo segment is estimated to grow at the fastest rate during the forecast period. In vivo, gene therapy allows for natural cell growth by directly inserting newly generated genetic material, typically DNA, into the cells. For genetic illnesses affecting a single gene in the body, in vivo approaches could be most advantageous. Additionally, targeting an inside organ like the heart is believed to be more advantageous. Targeting internal organs is made simpler by in vivo techniques. Furthermore, since removing a person's cells is unnecessary, it is less complex.

End-use Insights

By end-use, the biotechnology and pharmaceutical companies dominated the genome editing market in 2023. In biotechnology, genome editing is a field that has long been researched and exploited. Genome editing is used in biotechnology to investigate the roles of various genes. In addition, it is employed in the development of genetically modified organisms for a range of applications, including the production of vaccines, the development of genetically modified crops, the development of plant- or microbe-based products, such as human insulin, and so on. Vaccines and monoclonal antibodies are only two examples of the biopharmaceuticals that are now made using genetic engineering methods. By modifying the host organisms for increased yields and purity, genetic engineering enables researchers to maximize the synthesis of medicinal substances. The creation of tailored medicines is made possible by genetic engineering, which is crucial in this regard.

Regional Insights

By region, North America dominated the genome editing market in 2023. North America is known for its technological advancements, research, and development, which have led the market in the North American region. Countries like the U.S. and Canada significantly contribute to the market's growth. The majority of GMOs are regulated by three federal entities that are part of the US government. The term "genetically modified organism," or "GMO," is now often used by the public and media to refer to any plant, animal, or microorganism whose genetic material (DNA) has been modified by a procedure known as genetic engineering. The safety of genetically modified organisms (GMOs) for human, plant, and animal health is guaranteed by the U.S. Department of Agriculture (USDA), the Environmental Protection Agency (EPA), and the Food and Drug Administration (FDA).

In May 2022, USDA provided $32 million for community wood grants and wood innovation, utilizing an additional $93 million in partner money to support the creation of novel wood products and the efficient use of American forest resources. Additionally, DOE announced additional grants totaling around $178 million to support creative research projects in the fields of biotechnology, bioproducts, and biomaterials. Furthermore, over $200 million was invested in fortifying America's bio-economy through the $1 billion Build Back Better Regional Challenge, a program of the U.S. Economic Development Administration.

By region, Asia Pacific is expected to grow at the fastest rate during the forecast period. Asia Pacific is the largest continent and is significantly contributing to the growth of the genome editing market. The market is growing due to countries like China, Japan, India, and South Korea. These countries are showcasing technological advances and government investment for the growth of biotechnology, genetic engineering, agriculture, and healthcare.

The Department of Biotechnology (DBT) of the Government of India is spearheading the push to promote biotechnological innovation and entrepreneurship by harnessing the potential of strategic partnerships and building capacity across the country. From 6 in 2014 to over 75 in 2023, the number of bio-incubators increased. Approximately INR 4,500 Cr has been raised in follow-on financing by 150 enterprises. The bioeconomy of the country was estimated to be worth $137 billion in 2023 and is expected to reach $300 billion by 2030.

Public Opinion on Genome Editing for Different Medical Scenarios (in Japan)

GAs (N=10,881)

Pts (N=937)

Statement Understand what it means (N=723) Have heard of it (N=2,842) Have never heard of it (N=7,316) Understand what it means (N=123) Have heard of it (N=292) Have never heard of it (N=522)
Genome editing may be performed for diseases that shorten a baby's life 32.9% 25.9% 20.3% 30% 20% 20%
Genome editing may be performed for diseases that require long-term care 56.1% 61.0% 51.7% 52.6% 44.0% 36.6%
Not appropriate in any circumstances 10% 20% 30% 10% 20% 40%

The survey looked at how much people know and accept human germline genome editing, and how worried they are about it. It found that people who understand what it means are more likely to accept it for serious diseases. Both patients (PTs) and the general public (GAs) have concerns about genome editing, especially about humans changing other humans' genes. In fact, PTs who understand genome editing are worried about it being used to change human genes, and GAs share similar concerns.

Recent Developments in Genome Editing Market

  • In April 2024, the first open-source AI-generated gene editor was released today as part of the OpenCRISPRTM project by Profluent, the AI-first protein design business. Profluent's development of configurable gene editors created from scratch using AI represents the first successful instance of precision editing the human genome. Using Profluent's large language models (LLMs), OpenCRISPR-1 is an AI-generated gene editor that consists of a guide RNA and a Cas9-like protein.
  • In April 2024, Nvelop Therapeutics was established to enhance gene therapy delivery. Based on independently developed systems built by David Liu of the Broad Institute of MIT and Harvard and Keith Joung of Massachusetts General Hospital, the company was founded in 2022 with $100 million in backing from investors. The company is creating delivery systems for gene-editing cargo that resemble viruses.
  • In January 2024, a joint research facility between Danaher and the Innovative Genomics Institute (IGI) was established to create CRISPR-based gene treatments for various disorders. Based at the University of California, Berkeley, the center dubbed the Danaher-IGI Beacon for CRISPR Cures—will adopt a unified approach to the study, development, and regulation of gene-editing therapies for potentially hundreds of diseases.

Segments Covered in Genome Editing Market Report

By Application

  • Genetic Engineering
    • Cell Line Engineering
    • Animal Genetic Engineering
    • Plant Genetic Engineering
    • Others
  • Clinical Applications
    • Diagnostics
    • Therapy Development

By Technology

  • (CRISPR)/Cas9
  • TALENs/MegaTALs
  • ZFN
  • Meganuclease
  • Others

By Delivery Method

  • Ex-vivo
  • In-vivo

By End-use

  • Biotechnology and Pharmaceutical Companies
  • Academic and Government Research Institutes
  • Contract Research Organizations

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • MEA

Proceed To Buy

USD 5400
USD 3800
USD 2100
USD 2100
USD 7500

About The Author

Deepa has certified the degree of Master’s in Pharmacy in the Pharmaceutical Quality Assurance department from Dr D.Y. Patil College of Pharmacy. Her research is focused on the healthcare industry. She is the author or co-author of four Review Articles, which include Solid dispersion a strategic method for poorly soluble drugs and solubility improvement techniques for poorly soluble drugs, Herbal Drugs Used In Treatment Of Cataracts, Nano sponges And Their Application in Cancer Prevention and Ayurvedic Remedies of Peptic ulcer. She has also published a Research Article on the Formulation and Evaluation of Mucoadhesive Tablets of Miconazole cocrystal which was published in GIS Science Journal Volume 9 Issue 8. Her passion for secondary research and desire to take on the challenge of solving unresolved issues is making her flourish is the in the research sector.


Genetically engineered animal models of CVD have been made possible thanks to the development of CRISPR-based germline genome editing techniques. CRISPR-based gene editing techniques are quicker, simpler to use, and more widely applicable than traditional gene targeting methods that utilize embryonic stem cells.

In an effort to treat sickness or strengthen the body resistance to illness, gene therapy attempts to correct a damaged gene or replace it with a healthy one. Numerous illnesses, including cancer, AIDS, diabetes, heart disease, cystic fibrosis, and hemophilia, may benefit from it as a treatment.

World Health Organization, National Heart, Lung, and Blood Institute, FDA, The White House, USAD, Press Information Bureau.